Diagnosis and Prognostication of Ductal Adenocarcinomas of the Pancreas Based on Genome-Wide DNA Methylation Profiling by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification

Table 4

Multivariate analysis of clinicopathological parameters and DNA methylation profiles associated with recurrence-free and overall survival in patients with ductal adenocarcinomas of the pancreas.

	Recurrence-free survival			Overall survival
Parameters	Hazard ratio (95% CI∗)	χ ^2	P	Hazard ratio (95% CI)	χ ^2	P
Status of the surgical margin
Negative (R0∗∗, 𝑛=60)	1			1
Positive (R1 or R2 ∗∗, 𝑛=31)	1.072 (0.645–1.782)	0.071	.7898	1.452 (0.804–2.619)	1.531	.2159
Lymph node metastasis
Negative (𝑛=22)	1			1
Positive (𝑛=69)	1.621 (0.878–2.995)	2.383	.1227	1.477 (0.709–3.073)	1.086	.2973
The criteria in Table 3
Satisfying for less than 2 BAC clones (𝑛=10)	1			1
Satisfying for 2 or more BAC clones (𝑛=81)	18.694 (2.559–136.555)	8.331	.0039	12.136 (1.660–88.711)	6.051	.0139

∗ CI, confidence interval; ∗∗ defined in [28].